Kaycee M Sink is an expert in Neurology at Genentech Inc. (United States). As of July 2026, ScienceLeadR ranks Kaycee M Sink in the top 1% of experts worldwide for Cognitive Dysfunction, Cognition Disorders and Neurocognitive Disorders. Kaycee M Sink has authored 380 publications, the most recent in 2026, and is an investigator in 10 clinical trials. SLR score: 637 (community average: 125). How the SLR is computed.

LeadR Profile

Kaycee M Sink Genentech Inc. United States
637 ScienceLeadR Reputation 637
Network Map

Neurology

Subspecialties: Psychiatry - Geriatrics - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2004 - 2026

Source: PubMed

Genentech Inc.

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 380

Citations

Citations: 43 296 1st author: 10 Last author: 11 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Genetic modifiers of APOE-ε4-associated cognitive decline.
PMID 41720779 — language, biological science disciplines, genome, executive function, cognitive dysfunction, apolipoproteins e, cognition
Nat Commun20260
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1 Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.
PMID 41579901 — genes, safety, alzheimer disease, pharmaceutical preparations, biomarkers, signs and symptoms, drug-related side effects and adverse reactions, therapeutics, amyloid, nervous system, mutation
Lancet Neurol Top journal20260
The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity.
PMID 40603145 — activities of daily living, alzheimer disease, cognitive dysfunction, algorithms
J Prev Alzheimers Dis20250
Relationships of PGRN with sTREM2 in AD continuum and non-AD pathophysiology and their reciprocal roles in modulating amyloid pathology: two population-based study.
PMID 40628712 — pathology, biomarkers, amyloid, psychiatry
Transl Psychiatry20250
Higher Educational Attainment and Accelerated Tau Accumulation in Alzheimer Disease.
PMID 40622710 — alzheimer disease, aging, cohort studies, therapeutics, nervous system diseases, plasma
JAMA Neurol20252

Clinical Studies 10

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 4
N/A 3
Phase 2 2
Phase 1 1

By status:

Completed 9
Active not recruiting 1

By type:

Interventional 9
Observational 1

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 1
multicentric5to9 2
multicentricup10 3

Main Topics

Cohort/Consortium Investigators 54

LeadR Networks

Main global connection map